1. Home
  2. KYTX

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Founded: 2018 Country:
Canada
Canada
Employees: N/A City: EMERYVILLE
Market Cap: 590.7M IPO Year: 2024
Target Price: $39.50 AVG Volume (30 days): 384.7K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.76 EPS Growth: N/A
52 Week Low/High: $12.16 - $30.60 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 33.33%

Stock Insider Trading Activity of KYVERNA THERAPEUTICS INC (KYTX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Vida Ventures, LLC KYTX 10% Owner Feb 12 '24 Buy $22.00 252,553 $5,556,166.00 252,553 SEC Form 4
Vida Ventures, LLC KYTX 10% Owner Feb 12 '24 Buy $22.00 583 $12,826.00 583 SEC Form 4
Northpond Ventures III GP, LLC KYTX Feb 12 '24 Buy $22.00 450,000 $9,900,000.00 450,000 SEC Form 4
GILEAD SCIENCES, INC. KYTX 10% Owner Feb 12 '24 Buy $22.00 910,000 $20,020,000.00 4,126,119 SEC Form 4

Share on Social Networks: